Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation

Osimertinib is a standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor gene (EGFR) mutations, but most patients with EGFR-mutant NSCLC develop secondary resistance to osimertinib. Mesenchymal-epithelial transition gene (MET) alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamori, Shinkichi, Seto, Takashi, Yamaguchi, Masafumi, Kinoshita, Fumihiko, Fujishita, Takatoshi, Ito, Kensaku, Toyozawa, Ryo, Shoji, Fumihiro, Okamoto, Tatsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608750/
https://www.ncbi.nlm.nih.gov/pubmed/36313664
http://dx.doi.org/10.3389/fonc.2022.965741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608750/
https://www.ncbi.nlm.nih.gov/pubmed/36313664
http://dx.doi.org/10.3389/fonc.2022.965741

Ejemplares similares